Romidepsin (FK228, Depsipeptide)

Name: Romidepsin (FK228, Depsipeptide)
Brand: Selleck Chemicals
SKU: S3020
Rating: 5 (166 reviews)

For research use only.

Catalog No.S3020 Synonyms: FR 901228, NSC 630176

166 publications

Romidepsin (FK228, Depsipeptide) Chemical Structure

CAS No. 128517-07-7

Romidepsin (FK228, Depsipeptide, FR 901228, NSC 630176) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Selleck's Romidepsin (FK228, Depsipeptide) has been cited by 166 publications

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Nat Biotechnol, 2020, 10.1038/s41587-019-0388-4

PubMed: 31959954 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Nucleic Acids Res, 2021, 49(4):2390-2399

PubMed: 33544854 ( click the link to review the publication )

Neuro Oncol, 2021, 23(3):376-386

PubMed: 33130903 ( click the link to review the publication )

Cell Rep, 2021, 36(9):109643

PubMed: 34469719 ( click the link to review the publication )

Autophagy, 2021, 1-15

PubMed: 34034634 ( click the link to review the publication )

Oncogene, 2021, 10.1038/s41388-021-01931-1

PubMed: 34247191 ( click the link to review the publication )

Cancer Lett, 2021, 521:268-280

PubMed: 34481935 ( click the link to review the publication )

J Invest Dermatol, 2021, S0022-202X(21)01438-X

PubMed: 34284046 ( click the link to review the publication )

Cancers (Basel), 2021, 13(6)1376

PubMed: 33803654 ( click the link to review the publication )

Cancers (Basel), 2021, 13(2)E259

PubMed: 33445642 ( click the link to review the publication )

Cancers (Basel), 2021, 13(15)3862

PubMed: 34359763 ( click the link to review the publication )

Signal Transduct Target Ther, 2021, 6(1):333

PubMed: 34482361 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2021, 62(12):16

PubMed: 34533562 ( click the link to review the publication )

Genes (Basel), 2021, 12(2)260

PubMed: 33670166 ( click the link to review the publication )

Dev Dyn, 2021, 10.1002/dvdy.294

PubMed: 33410213 ( click the link to review the publication )

Anal Biochem, 2021, 628:114286

PubMed: 34119487 ( click the link to review the publication )

SLAS Discov, 2021, 2472555220983810

PubMed: 33427012 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Int J Radiat Biol, 2021, 1-15

PubMed: 33979259 ( click the link to review the publication )

Transl Psychiatry, 2021, 11(1):99

PubMed: 33542189 ( click the link to review the publication )

EBioMedicine, 2021, 65:103241

PubMed: 33647768 ( click the link to review the publication )
Eur J Immunol, 2021, 10.1002/eji.202048892

PubMed: 33555624 ( click the link to review the publication )

Cancers (Basel), 2021, 13(2)E259

PubMed: 33445642 ( click the link to review the publication )

Clin Epigenetics, 2021, 13(1):41

PubMed: 33632300 ( click the link to review the publication )

J Dermatol Sci, 2021, S0923-1811(21)00005-0

PubMed: 33531202 ( click the link to review the publication )

Life Sci, 2021, 271:119127

PubMed: 33515561 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5775

PubMed: 33188175 ( click the link to review the publication )

EMBO Rep, 2020, 21:e50162

PubMed: 32314873 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33046

PubMed: 32599665 ( click the link to review the publication )

PLoS Pathog, 2020, 16(2):e1008151

PubMed: 32109259 ( click the link to review the publication )

Cells, 2020, 10;9(6):E1447

PubMed: 32532133 ( click the link to review the publication )

J Immunol, 2020, 204(5):1242-1254

PubMed: 31988180 ( click the link to review the publication )

J Virol, 2020, 16;94(9) pii: e01845-19

PubMed: 32051267 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

HIV Med, 2020, 21(11):747-757

PubMed: 33369029 ( click the link to review the publication )

Am J Transl Res, 2020, 12(10):6187-6203

PubMed: 33194023 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 4;526(3):612-617

PubMed: 32247610 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Blood Adv, 2020, 4(5):819-829

PubMed: 32126142 ( click the link to review the publication )

Sci Rep, 2020, 10(1):12864

PubMed: 32733053 ( click the link to review the publication )

Cancer Immunol Immunother, 2020, 10.1007/s00262-020-02653-1

PubMed: 32632663 ( click the link to review the publication )

Oncotarget, 2020, 11(37):3432-3442

PubMed: 32973968 ( click the link to review the publication )

Cancers (Basel), 2020, 12(12)E3589

PubMed: 33266275 ( click the link to review the publication )

Genes Chromosomes Cancer, 2020, 10.1002/gcc.22884

PubMed: 32614991 ( click the link to review the publication )
Front Immunol, 2020, 11:1746

PubMed: 33013828 ( click the link to review the publication )

Med Sci Monit, 2020, 26:e918528

PubMed: 31954012 ( click the link to review the publication )

PeerJ, 2020, 8:e10321

PubMed: 33282555 ( click the link to review the publication )

Epigenetics, 2020, 15(4):369-385

PubMed: 31533525 ( click the link to review the publication )

J Clin Invest, 2020, 135711

PubMed: 33270606 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2189

PubMed: 31097698 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(3):513-526

PubMed: 30521971 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 30979734 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Clin Infect Dis, 2019, 10.1093/cid/ciz108

PubMed: 30753360 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2152

PubMed: 31772119 ( click the link to review the publication )

Cell Rep, 2019, 29(9):2783-2795

PubMed: 31775045 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.44306

PubMed: 31050342 ( click the link to review the publication )

J Hematol Oncol, 2019, 12(1):30

PubMed: 30885250 ( click the link to review the publication )

Mol Ther, 2019, 27(5):1039-1050

PubMed: 30852137 ( click the link to review the publication )

Cancers (Basel), 2019, 11(5)E645

PubMed: 31083396 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)E1871

PubMed: 31769432 ( click the link to review the publication )

PLoS Pathog, 2019, 15(8):e1007991

PubMed: 31425551 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(5):937-951

PubMed: 31649844 ( click the link to review the publication )

Front Immunol, 2019, 9:3162

PubMed: 30723480 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Oncologist, 2019, 24(8):e740-e748

PubMed: 30696721 ( click the link to review the publication )

Mol Neurobiol, 2019, 10.1007/s12035-019-1565-7

PubMed: 30963442 ( click the link to review the publication )

AIDS, 2019, 33(2):199-209

PubMed: 30562171 ( click the link to review the publication )
Pharmacol Res, 2019, 142:192-204

PubMed: 30807866 ( click the link to review the publication )

Arthritis Res Ther, 2019, 21(1):50

PubMed: 30728075 ( click the link to review the publication )

Apoptosis, 2019, 24(5-6):404-413

PubMed: 30997620 ( click the link to review the publication )

J Biol Chem, 2019, 294(14):5576-5589

PubMed: 30745362 ( click the link to review the publication )

Exp Cell Res, 2019, 375(2):106-112

PubMed: 30579954 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):79

PubMed: 30651077 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 510(2):278-283

PubMed: 30686534 ( click the link to review the publication )

ACS Omega, 2019, 4(22):19895-19904

PubMed: 31788622 ( click the link to review the publication )

Virus Res, 2019, 269:197631

PubMed: 31136823 ( click the link to review the publication )

American Association for Cancer Research, 2019, 10.1158/1078-0432.CCR-18-3989

PubMed: None ( click the link to review the publication )

Oncotarget, 2019, 10(55):5671-5679

PubMed: 31620242 ( click the link to review the publication )

J Nanobiotechnology, 2019, 17(1):69

PubMed: 31113488 ( click the link to review the publication )

J Virus Erad, 2019, 5(3):133-137

PubMed: 31700655 ( click the link to review the publication )

Blood, 2018, 131(4):397-407

PubMed: 29141948 ( click the link to review the publication )

J Clin Invest, 2018, 128(10):4413-4428

PubMed: 30148456 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2024

PubMed: 29789628 ( click the link to review the publication )

Haematologica, 2018, 103(4):679-687

PubMed: 29305415 ( click the link to review the publication )

Int J Cancer, 2018, 143(6):1388-1401

PubMed: 29633255 ( click the link to review the publication )

MBio, 2018, 9(6)

PubMed: 30425153 ( click the link to review the publication )

Clin Epigenetics, 2018, 10:01

PubMed: 29312470 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

Cell Prolif, 2018, 51(3):e12447

PubMed: 29484736 ( click the link to review the publication )

J Virol, 2018, 92(13)

PubMed: 29643247 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )
Sci Rep, 2018, 8(1):1400

PubMed: 29362442 ( click the link to review the publication )

Stem Cells Int, 2018, 2018:2379546

PubMed: 29731773 ( click the link to review the publication )

Stem Cells Dev, 2018, 27(17):1215-1225

PubMed: 30032710 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)E505

PubMed: 30544928 ( click the link to review the publication )

Curr Protoc Pharmacol, 2018, 81(1):e41

PubMed: 29927058 ( click the link to review the publication )

Genome Res, 2018, 10.1101/gr.227272.117

PubMed: 29429976 ( click the link to review the publication )

Nat Neurosci, 2018, 21(4):564-575

PubMed: 29531362 ( click the link to review the publication )

JCI Insight, 2018, 3(22)125568

PubMed: 30429379 ( click the link to review the publication )

Nat Commun, 2017, 8(1):403

PubMed: 28864822 ( click the link to review the publication )

Nat Commun, 2017, 8(1):939

PubMed: 29038521 ( click the link to review the publication )

Genes Dev, 2017, 31(17):1770-1783

PubMed: 28982760 ( click the link to review the publication )

Cancer Immunol Res, 2017, 5(7):604-616

PubMed: 28615266 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3084-3096

PubMed: 27993968 ( click the link to review the publication )

Kidney Int, 2017, 92(3):669-679

PubMed: 28416226 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

FEBS J, 2017, 284(23):4035-4050

PubMed: 28985013 ( click the link to review the publication )

J Virol, 2017, 91(24)e01080-17

PubMed: 29021396 ( click the link to review the publication )

Biochem Pharmacol, 2017, 127:90-100

PubMed: 28012958 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(5)

PubMed: 28481295 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(4):551-560

PubMed: 28112184 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2017, 7(1):42-50

PubMed: 28107750 ( click the link to review the publication )

JCI Insight, 2017, 2(1):e85811

PubMed: 28097226 ( click the link to review the publication )
Oncotarget, 2017, 8(4):6319-6329

PubMed: 28030834 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3908-3921

PubMed: 29423093 ( click the link to review the publication )

Oncotarget, 2017, 8(30-:48737-48754

PubMed: 28467787 ( click the link to review the publication )

Ann Oncol, 2016, 27(3):508-13

PubMed: 26658891 ( click the link to review the publication )

EMBO Mol Med, 2016, 8(2):117-38

PubMed: 26681773 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(16):4119-32

PubMed: 26964571 ( click the link to review the publication )

Kidney Int, 2016, 89(2):317-26

PubMed: 26509586 ( click the link to review the publication )

EBioMedicine, 2016, 8:217-229

PubMed: 27428432 ( click the link to review the publication )

PLoS Pathog, 2016, 12(4):e1005545

PubMed: 27082643 ( click the link to review the publication )

J Virol, 2016, 90(20):9018-28

PubMed: 27466424 ( click the link to review the publication )

Sci Rep, 2016, 6:30749

PubMed: 27480951 ( click the link to review the publication )

Int J Neuropsychopharmacol, 2016, 10.1093/ijnp/pyw035

PubMed: 27207921 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2453-2463

PubMed: 27748897 ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2016, 311(5):H1139-H1149

PubMed: 27638876 ( click the link to review the publication )

Oncol Rep, 2016, 36(4):1875-85

PubMed: 27509880 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 474(1):71-75

PubMed: 27091426 ( click the link to review the publication )

Leuk Res, 2016, 47:100-8

PubMed: 27294334 ( click the link to review the publication )

Target Oncol, 2016, 11(6):783-798

PubMed: 27250763 ( click the link to review the publication )

Oncotarget, 2016, 7(7):7715-31

PubMed: 26735339 ( click the link to review the publication )

Oncotarget, 2016, 10.18632/oncotarget.8379

PubMed: 27028869 ( click the link to review the publication )

Oncotarget, 2016, 7(4):4454-67

PubMed: 26683357 ( click the link to review the publication )

Nat Commun, 2015, 3;6:10091

PubMed: 26631872 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-1561

PubMed: ( click the link to review the publication )
Leukemia, 2015, 29(3):556-66

PubMed: 25118879 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(7):1628-38

PubMed: 25623213 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e357

PubMed: 26473529 ( click the link to review the publication )

Endocr Relat Cancer, 2015, 22(5):777-92

PubMed: 26206775 ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(7):3984-94

PubMed: 25896701 ( click the link to review the publication )

Sci Rep, 2015, 5:16445

PubMed: 26563568 ( click the link to review the publication )

J Biol Chem, 2015, 290(39):23725-37

PubMed: 26269591 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: 25540204 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2015, 5(3):117-26

PubMed: 26199860 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0145994

PubMed: 26717578 ( click the link to review the publication )

Tumour Biol, 2015, 36(7):5485-95

PubMed: 26036758 ( click the link to review the publication )

Clin Cancer Res, 2014, 10.1158/1078-0432.CCR-14-0384

PubMed: 25355930 ( click the link to review the publication )

Diabetes, 2014, 63(9):2924-34

PubMed: 24722245 ( click the link to review the publication )

PLoS Pathog, 2014, 10(8):e1004287

PubMed: 25122219 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(7):1280-9

PubMed: 24469401 ( click the link to review the publication )

J Chem Inf Model, 2014, 10.1002/ijc.28924

PubMed: 24771510 ( click the link to review the publication )

J Neurosci, 2013, 33(17):7535-47

PubMed: 23616558 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(8):1591-604

PubMed: 23536727 ( click the link to review the publication )

Br J Haematol, 2013, 162(4):559-62

PubMed: 23692150 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Features

More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.

Targets

HDAC1 ^[1] (Cell-free assay)	HDAC2 ^[1] (Cell-free assay)
36 nM	47 nM

In vitro

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. ^[1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. ^[2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. ^[3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. ^[5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. ^[6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. ^[7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. ^[9]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
SU-DHL4	M3\6TmNmdGxiVnnhZoltcXS7IFHzd4F6	NXnLcnA{Oi53LUG1JI5O	MU[3NkBp		NXfDSmlPcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd7MEmwO{c,OjV5OUC5NFc9N2F-
U2932	NFnmepdE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MX6yMlUuOTVibl2=	MmXhO\|IhcA>?		NIr6VYVqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi	MojvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OUC5NFcoRjJ3N{mwPVA4RC:jPh?=
OCI-LY7	MWjD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M2\3UVIvPS1zNTDuUS=>	MonsO\|IhcA>?		MkXvbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>?	NEjPbYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe5NFkxPyd-MkW3PVA6ODd:L3G+
Farage	M2TReWNmdGxiVnnhZoltcXS7IFHzd4F6	MWiyMlUuOTVibl2=	NXv6c49ZPzJiaB?=		M{\Hcolv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB?	NEjteHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe5NFkxPyd-MkW3PVA6ODd:L3G+
LY7/EBV	MkLuR4VtdCCYaXHibYxqfHliQYPzZZk>	MoC4Nk42NTF3IH7N	M{\HfVczKGh?		M1G2eIlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB?	NWDkRpY6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PVA6ODdpPkK1O\|kxQTB5PD;hQi=>
U2932/EBV	NE\RcWZE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NYPsOYlMOi53LUG1JI5O	MmHmO\|IhcA>?		M3fnRolv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB?	NH;sbYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe5NFkxPyd-MkW3PVA6ODd:L3G+
HCT116	NIH4[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPZd4c2NTVyMECgcm0>	M16yNlI1KGh?	NFPqcI5FVVOR	NXLmd3RjcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz	NFHIVmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS5NlUyPSd-MkW0PVI2OTV:L3G+
ACH-2	MnTGSpVv[3Srb36gRZN{[Xl?	NFnPXZEyNTlibl2=	MVKyOEBp		NUfxeFdmcW6mdXPld{BJUVZvMTDFcpYh\XiycnXzd4lwdg>?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF2OUS2O{c,OjVzNEm0Olc9N2F-
MCF-10A	M1TSPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWmyNVU{UUN3ME2wMlE4yrFyLkCxJI5O	M4rRO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUW0PFU3Lz5{NEm1OFg2PjxxYU6=
MCF-7	NGDHeYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLUUop7UUN3ME2xMlExyrFyLkKwJI5O	NGnj[489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm1OFg2Pid-MkS5OVQ5PTZ:L3G+
SK-BR-3	MlrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTFwMEFCtVAvOzVibl2=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl3NEi1Okc,OjR7NUS4OVY9N2F-
MDA-MB-231	NWG3S4FZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELLdIRKSzVyPUCuOljDuTBwMUSgcm0>	M3vlN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUW0PFU3Lz5{NEm1OFg2PjxxYU6=
PC3	NVX6TGppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfWVHJKSzVyPUGuOlXDuTBwM{Wgcm0>	NUTaPVZwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OVQ5PTZpPkK0PVU1QDV4PD;hQi=>
HCT116	MmPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlm1TWM2OD1zLkCwxtExNjByIH7N	M3XiSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUW0PFU3Lz5{NEm1OFg2PjxxYU6=
HCT116-p21-/-	NH:5UXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfYW5dKSzVyPUGuNlbDuTBwM{egcm0>	NH:0W5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm1OFg2Pid-MkS5OVQ5PTZ:L3G+
S1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MojITWM2OD15Lk[3xtExNjJ7IH7N	MoTJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUS4OVYoRjJ2OUW0PFU3RC:jPh?=
SW620	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jPdGlEPTB;MD65N:KyOC5{OTDuUS=>	MnHTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUS4OVYoRjJ2OUW0PFU3RC:jPh?=
LOX-IMVI	Mmj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTBwOEhCtVAvODNibl2=	M2TMVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUW0PFU3Lz5{NEm1OFg2PjxxYU6=
UACC-62	Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2K5[WlEPTB;MD61OuKyOC5zNjDuUS=>	MkP0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUS4OVYoRjJ2OUW0PFU3RC:jPh?=
MDA-MB-435	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTBwOUFCtVAvODZibl2=	MljDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUS4OVYoRjJ2OUW0PFU3RC:jPh?=
SF-295	M2DJ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmDCTWM2OD1yLki4xtExNjF3IH7N	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl3NEi1Okc,OjR7NUS4OVY9N2F-
A549	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHj2SVNKSzVyPUGuNlbDuTBwMkSgcm0>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl3NEi1Okc,OjR7NUS4OVY9N2F-
H460	NFLC[INIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXtTWM2OD1{LkW4xtExNjhyIH7N	M165bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUW0PFU3Lz5{NEm1OFg2PjxxYU6=
EKVX	M1vjSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTQeXpKSzVyPUGuN\|PDuTBwM{Sgcm0>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl3NEi1Okc,OjR7NUS4OVY9N2F-
H146	M3zhW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7jeYZ3UUN3ME2wMlIzyrFyLkC3JI5O	MlrsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUS4OVYoRjJ2OUW0PFU3RC:jPh?=
H526	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rEcmlEPTB;MD6xOeKyOC5yMzDuUS=>	M4fnNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUW0PFU3Lz5{NEm1OFg2PjxxYU6=
HuT-78	NUThUmRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTFwN{RCtVAvPDRibl2=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl3NEi1Okc,OjR7NUS4OVY9N2F-
HA	M2rMN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LUflAvPjJ3LUGwcm0>	Mki0OFghcA>?		MWXpcoR2[2W\|IHGgd4lodmmoaXPhcpRtgSC\|dILvcodmeiCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBkdy22cnXheIVlKHerdHigZo9zfGW8b33pZi=>	NIe1RoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe3NVUyOCd-MkS3O\|E2OTB:L3G+
MS-275	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWT4WI1QOC54MkWtNVBvVQ>?	MlLxOFghcA>?		MULpcoR2[2W\|IHGgd4lodmmoaXPhcpRtgSC\|dILvcodmeiCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBkdy22cnXheIVlKHerdHigZo9zfGW8b33pZi=>	NHXzVVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe3NVUyOCd-MkS3O\|E2OTB:L3G+
CD4 T	NHvrPWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{TkNVQ5KGh?		NYDX[pJmTUN3ME20MlXDuTFwMDDuUS=>	Mnr6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5MkK0OVQoRjJ2N{KyOFU1RC:jPh?=
CD4 T	MlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWC0PEBp		MYnDR\|UxRTFyN9MxNVI3KG6P	NYfaXJVzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3NlI1PTRpPkK0O\|IzPDV2PD;hQi=>
CD4+ T	NUKwNmo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXiNot1TUN3ME2zJI5O	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR7NUGwOUc,OjR2OUWxNFU9N2F-
A549	NXuzb\|EyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13CN\|Ex6oDVMUCwxsBvVQ>?	NIizTXIzPC9\|Nj:0PEBp		MXLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJINwdmOnboTyZZRqd25vIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ?	MlLaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OEW3PVkoRjJ2NEi1O\|k6RC:jPh?=
JJN3	M4\FR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXmyOE81QCCq		NFXMSmJGSzVyPEJihKlvVTtiNElihKlp	NY[zR\|FpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwN\|AyPTBpPkK0NFMxOTVyPD;hQi=>
OPM-2	NFP0RopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlLmNlQwPDhiaB?=		MonNSWM2OHN;MfMAjY5OQyB2OPMAjYg>	NV;xdmJNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwN\|AyPTBpPkK0NFMxOTVyPD;hQi=>
RPMI-8226	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlLvNlQwPDhiaB?=		NVPJXGZRTUN3MIO9NU456oDLbl27JFQ56oDLaB?=	MmnJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyM{CxOVAoRjJ2MEOwNVUxRC:jPh?=
U266	NEDjcGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MX:yOE81QCCq		NVvYXmxtTUN3MIO9NVDjiImwTUugOFjjiImq	NHjMWZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECzNFE2OCd-MkSwN\|AyPTB:L3G+
CA46	MUnBdI9xfG:\|aYOgRZN{[Xl?		NETG[oE3KGh?		MlXmbY5lfWOnczDicJVvfCCjcH;weI9{cXN?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4NkG2OEc,OjN7Nk[xOlQ9N2F-
DG75	M2DQ[GFxd3C2b4Ppd{BCe3OjeR?=		MlrGOkBp		Mo\3bY5lfWOnczDuc{BieG:ydH;zbZM>	NFrhd4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2OlE3PCd-MkO5OlYyPjR:L3G+
Ramos	NVPUbllJSXCxcITvd4l{KEG\|c3H5		MXO2JIg>		NVzyVHFIcW6mdXPld{BmgHSnboPpeoUh[XCxcITvd4l{	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4NkG2OEc,OjN7Nk[xOlQ9N2F-
ST486	Ml\PRZBweHSxc3nzJGF{e2G7		MVi2JIg>		NVfVUI9lcW6mdXPld{BmgHSnboPpeoUh[XCxcITvd4l{	NFP2XWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2OlE3PCd-MkO5OlYyPjR:L3G+
HuT78	M4jSRWFxd3C2b4Ppd{BCe3OjeR?=	MmDBNU8yOC9zMECgcm0>	M1S3SVQ5KGh?		NICxZmtqdmS3Y3XzJIFxd3C2b4Ppd{BifCBzIH7N	M1fnelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUOyO\|MzLz5{M{WzNlc{OjxxYU6=
DpVp35	MYfBdI9xfG:\|aYOgRZN{[Xl?	M33aRlEwOTBxMUCwJI5O	NILIZYM1QCCq		MkKxbY5lfWOnczDicJVvfCCjcH;weI9{cXN?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV\|MkezNkc,OjN3M{K3N\|I9N2F-
DpVp50	MXPBdI9xfG:\|aYOgRZN{[Xl?	MXixM\|ExNzFyMDDuUS=>	M1HvOlQ5KGh?		MnrSbY5lfWOnczDicJVvfCCjcH;weI9{cXN?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV\|MkezNkc,OjN3M{K3N\|I9N2F-
DpP75	MVzBdI9xfG:\|aYOgRZN{[Xl?	M{\GVlEwOTBxMUCwJI5O	NE\vZ\|I1QCCq		MXnpcoR2[2W\|IHLseY51KGGyb4D0c5Nqew>?	Mn3OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3M{K3N\|IoRjJ\|NUOyO\|MzRC:jPh?=
SKOV-3	MkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXS[3g5OeLCk{Kwcm0>	MYS3NkBp	M2nU[WROW09?	NHHBcllz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>?	NGPRV3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CxNFM1QCd-MkOwNVA{PDh:L3G+
Brca1 WT	NHLzdmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX:x5qCUOjCwTR?=	MoHjO\|IhcA>?	NHPpVotFVVOR	MlPNdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4>	NUXCVZd4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNVA{PDhpPkKzNFExOzR6PD;hQi=>
Brca1 Null	NHLTbHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPxNgKBmzJybl2=	M1fLNFczKGh?	NIG4dFVFVVOR	NUPoO2U5emWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzBzMEO0PEc,OjNyMUCzOFg9N2F-
OVCAR-8	M33PVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVGx5qCUOjCwTR?=	NULh[HBuPzJiaB?=	M2HYTWROW09?	NVnpeldOemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5?	MlfzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyMUCzOFgoRjJ\|MEGwN\|Q5RC:jPh?=
NCI/ADR-RES	Mnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPOOVAy6oDVMkDuUS=>	MkntO\|IhcA>?	NYnJOI5yTE2VTx?=	NWDvemQzemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5?	M{fPcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEGwN\|Q5Lz5{M{CxNFM1QDxxYU6=
HCT116	NWHBXYxET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHx[VY2KG6PLUWwJO69VQ>?	MWWyOEBp	M4XzSmROW09?	NGXx[oFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>?	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl{NEm1PEc,OjJ7MkS5OVg9N2F-
RKO	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\SOUBvVS13MDFOwG0>	MojmNlQhcA>?	M1TpdmROW09?	NWXXZndLcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ?	MlfaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7MkS5OVgoRjJ{OUK0PVU5RC:jPh?=
CO115	NWfOZYRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjhXVU2KG6PLUWwJO69VQ>?	NWrDd2hPOjRiaB?=	M4\QcGROW09?	MmfzbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI>	M4Dn[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUK0PVU5Lz5{MkmyOFk2QDxxYU6=
HFS	M{n1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HFcFUhdk1?	NYLBS\|VTOjRxNEivO\|IhcA>?		NFO4TopqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6	MkjwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzME[yPFIoRjJ{MUC2NlgzRC:jPh?=
LNCaP	NH\adolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;QTIpFPSCwTR?=	MUGyOE81QC95MjDo		NInsPJRqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6	NIXaSGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkGwOlI5Oid-MkKxNFYzQDJ:L3G+
A549	NHXkenBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fsSVUhdk1?	MlLKNlQwPDhxN{KgbC=>		MkHabY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=>	NVL0UnRCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxNFYzQDJpPkKyNVA3Ojh{PD;hQi=>
697	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILEcY5KSzVy4pEJQgKBkTJwNdMgcm0>	NIj0OHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUWzPFIyPid-MkG1N\|gzOTZ:L3G+
697-R	NHnpXlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHr[W1pUUN3MPMAjV3jiIl6LkdCpI5OyqB?	MlHiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3M{iyNVYoRjJzNUO4NlE3RC:jPh?=
HUT78	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTFibl2=	NH3NT5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG5PFU1PSd-MkGxPVg2PDV:L3G+
THJ-16T	NETHOYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjTVYsyKG6P	NYm0d\|NzOjRiaB?=		NE\6dodqdmirYnn0d{Bk\WyuIHfyc5d1cA>?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODhzMEW2PEc,OjB6MUC1Olg9N2F-
HCT116	MoHRSpVv[3Srb36gRZN{[Xl?	NVvG[mhjOjBibl2=	M1HPVVghcA>?		MoPscY9lfWyjdHXzJJRz[W6\|Y4LpdJQhdGW4ZXzzJIZweiCqdX7kdoVleyCxZjDn[Y5meyCrbjDlbZRp\XJiZHny[YN1cW:w	M1vt[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyN{O5OFU1Lz5{MEezPVQ2PDxxYU6=
B104	MYPGeY5kfGmxbjDBd5NigQ>?	NXLFUYJ2OiCwTR?=	MXuyOE81QC95MjDo		NILTcWtqdmO{ZXHz[ZMhfGinIIP1doZi[2ViZYjwdoV{e2mxbjDv[kBETDJywrC=	NYjZbZlCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2PFY2ODVpPkKwOlg3PTB3PD;hQi=>
HL-60	M4e4fWN6fG:2b4jpZ4l1gSCDc4PhfS=>	NXTSXYtMOS13MECgcm0>	MnXUNlQhcA>?		M4joU4lv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB?	NIDFWHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[yOFE3Oyd-MkC2NlQyPjN:L3G+
HP100	M2\EemN6fG:2b4jpZ4l1gSCDc4PhfS=>	M1nvOVEuPTByIH7N	NYHjXJJqOjRiaB?=		NFXM[XVqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi	Mm\yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4MkSxOlMoRjJyNkK0NVY{RC:jPh?=
HL-60	M1jXN2Z2dmO2aX;uJGF{e2G7	M2\sWlExKG6P	NUfxWmtKPC94L{G2JIg>		MVnpcoR2[2W\|IITo[UBo\W6ncnH0bY9vKG:oIHj5[JJw\2WwIIDldo95cWSnIH\yc40hPGh?	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ{NEG2N{c,OjB4MkSxOlM9N2F-
HP100	Mnr5SpVv[3Srb36gRZN{[Xl?	NEC1[IEyOCCwTR?=	NVPj[GpZPC94L{G2JIg>		M1HhTolv\HWlZYOgeIhmKGenbnXyZZRqd25ib3[gbJllem:pZX6gdIVzd3irZHWg[pJwdSB2aB?=	M1LUeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNkK0NVY{Lz5{ME[yOFE3OzxxYU6=
HL-60	MVzGeY5kfGmxbjDBd5NigQ>?	MkfGNVAuPTByIH7N	NXjxeZZTPCCq		M3vVOIRm[3KnYYPld{B1cGViaHnzeI9v\SCmZXHj[ZR6dGG\|ZTCoTGRCSyliYXP0bZZqfHoEoB?=	MnzGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4MkSxOlMoRjJyNkK0NVY{RC:jPh?=
HP100	NITBUVNHfW6ldHnvckBCe3OjeR?=	MUOxNE02ODBibl2=	NILJZXo1KGh?		MX;k[YNz\WG\|ZYOgeIhmKGirc4TvcoUh\GWjY3X0fYxie2ViKFjERWMqKGGldHn2bZR6yqB?	M2e2VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNkK0NVY{Lz5{ME[yOFE3OzxxYU6=
11z	NVjOU2VDU2mwYYPlJGF{e2G7	NWrMXYNkOy1zMECgcm0>			MV7y[YR2[2W\|IFjERWMh\W68eX3heIlkKGGldHn2bZR6KCiLQ{WwxsA:KDZwNTFCtUAxNjZibn3vcE9NMQ>?	NGXtcm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[wOVE1PCd-MkC2NFUyPDR:L3G+
SKOV-3	NEXDe\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjhPVZ4PC96L{G2JI5O	M1;vOlQ5KGh?		M2\yfolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz	NVzoS3lURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0NFQ2PjRpPkKwOFA1PTZ2PD;hQi=>
OVCAR-3	MmLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYW5U5ZXPC96L{G2JI5O	MlKxOFghcA>?		Ml32bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODRyNEW2OEc,OjB2MES1OlQ9N2F-
HBL-2	NFn4WFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWqyMVExKG6P	MlPaNlQhcA>?		Mk\QTWM2OD12LkOgcm0>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB4OEC4NEc,OjByNkiwPFA9N2F-
Jeko-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUeyMVUxKG6P	MYeyOEBp		MVHJR\|UxRTFzIH7N	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB4OEC4NEc,OjByNkiwPFA9N2F-
Granta-519	Mnj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLuZYU2NTRyIH7N	M4nyOFI1KGh?		MVLJR\|UxRTV6LkWgcm0>	M2nnelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyME[4NFgxLz5{MEC2PFA5ODxxYU6=
L1236	M375bGN6fG:2b4jpZ4l1gSCDc4PhfS=>	Mom3NUBvVS1zMECg{txO	M{S4cVQ5KGh?		NVjldpdvTUN3ME2wMlA4KM7:TR?=	MnvLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{M{O0O\|AoRjF7MkOzOFcxRC:jPh?=
L428	NFy1RldEgXSxdH;4bYNqfHliQYPzZZk>	NFjJU24yKG6PLUGwNEDPxE1?	NG\6fY41QCCq		M1LEPWVEPTB;MD60N{DPxE1?	NGKxe3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKzN\|Q4OCd-MUmyN\|M1PzB:L3G+
KM-H2	NYLDVos2S3m2b4TvfIlkcXS7IFHzd4F6	NUTYbHZvOSCwTT2xNFAh\|ryP	MWK0PEBp		M4q2[2VEPTB;MD61PEDPxE1?	NITrR5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKzN\|Q4OCd-MUmyN\|M1PzB:L3G+
L540Cy	NYTPVlRkS3m2b4TvfIlkcXS7IFHzd4F6	Mkn1NUBvVS1zMECg{txO	M3zUdFQ5KGh?		MU\FR\|UxRTBwMU[g{txO	NHK2Omo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKzN\|Q4OCd-MUmyN\|M1PzB:L3G+
G401	M{X6c2Z2dmO2aX;uJGF{e2G7	MmTYNVAhdk1?	NF;2VGczPC92OD:3NkBp	MY\EUXNQ	M2Dq[olv[3KnYYPld{BETEuQMVOg[ZhxemW\|c3nvci=>	MnjqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{MkG1PFYoRjF7MkKxOVg3RC:jPh?=
STM91-01	NEjuVFJHfW6ldHnvckBCe3OjeR?=	NIHYNHkyOCCwTR?=	NIDlNnQzPC92OD:3NkBp	MnLiSG1UVw>?	M1nmdIlv[3KnYYPld{BETEuQMVOg[ZhxemW\|c3nvci=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ{MUW4Okc,OTl{MkG1PFY9N2F-
SJSC	NIPNd3RHfW6ldHnvckBCe3OjeR?=	NHziVYQyOCCwTR?=	M{\NWFI1NzR6L{eyJIg>	MoHJSG1UVw>?	M2W3bolv[3KnYYPld{BETEuQMVOg[ZhxemW\|c3nvci=>	M3qzcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkKxOVg3Lz5zOUKyNVU5PjxxYU6=
BT16	NYPwVWt{TnWwY4Tpc44hSXO\|YYm=	M2DYeFExKG6P	NELWWm0zPC92OD:3NkBp	M2Wzd2ROW09?	MojvbY5kemWjc3XzJGNFU05zQzDlfJBz\XO\|aX;u	MmG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{MkG1PFYoRjF7MkKxOVg3RC:jPh?=
NCI-H1299	M4[4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTRwNtMxNE4zKG6pL33s	NISwOZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUG3PVg6OCd-MUmxO\|k5QTB:L3G+
NCI-2882	M{XpPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnO[2VxUUN3ME2xMlbDuTBwMESgcocwdWx?	NWD0PIx1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxO\|k5QTBpPkG5NVc6QDlyPD;hQi=>
HCC95	MoXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jzNGlEPTB;Mj61xtExNjB3IH7nM41t	M4PoclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUe5PFkxLz5zOUG3PVg6ODxxYU6=
NCI-H23	NWLLNZNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2j2bWlEPTB;Mj65xtExNjJibnevcYw>	NYfydJp5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxO\|k5QTBpPkG5NVc6QDlyPD;hQi=>
NCI-H157	NVrFZVEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHuwW2JKSzVyPUGuOuKyOC5yMjDu[{9udA>?	NG\lS2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUG3PVg6OCd-MUmxO\|k5QTB:L3G+
NCI-H460	Mmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M12wOmlEPTB;Mj6xxtExNjB5IH7nM41t	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTF5OUi5NEc,OTlzN{m4PVA9N2F-
NCI-H1975	NW\DVXE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTQTWM2OD1zLkRCtVAvODRibnevcYw>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTF5OUi5NEc,OTlzN{m4PVA9N2F-
NCI-H820	M2i5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvsTWM2OD1{LkVCtVAvOSCwZz;tcC=>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTF5OUi5NEc,OTlzN{m4PVA9N2F-
NCI-H1650	MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{n6U2lEPTB;ND65xtExNjNibnevcYw>	MorPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzN{m4PVAoRjF7MUe5PFkxRC:jPh?=
DTC1	NWLWd25ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYDse3l7UUN3ME2wMlUyKG6P	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV4NkK0Okc,OTh3Nk[yOFY9N2F-
KAO	M2D2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTBwOUGgcm0>	MlrGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3Nk[yOFYoRjF6NU[2NlQ3RC:jPh?=
SU-CCS-1	M1;I[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmfGTWM2OD1yLki5JI5O	NHzNXW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW2OlI1Pid-MUi1OlYzPDZ:L3G+
SYO-1	Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MU\JR\|UxRTBwNkegcm0>	NGfhc2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW2OlI1Pid-MUi1OlYzPDZ:L3G+
FUJI	NFzTeXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPteVZOUUN3ME2xMlMyKG6P	Mm\qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3Nk[yOFYoRjF6NU[2NlQ3RC:jPh?=
SKNMC	MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTFwMUegcm0>	M3j6VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NU[2NlQ3Lz5zOEW2OlI1PjxxYU6=
402-91	MknVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTFwMk[gcm0>	MnjoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3Nk[yOFYoRjF6NU[2NlQ3RC:jPh?=
1765-92	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTFwN{egcm0>	M4raT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NU[2NlQ3Lz5zOEW2OlI1PjxxYU6=
JN-DSRCT-1	MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfuTWM2OD1zLkK1JI5O	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV4NkK0Okc,OTh3Nk[yOFY9N2F-
NMS-2PC	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHNTWM2OD1yLkixJI5O	NX\XblhbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1OlYzPDZpPkG4OVY3OjR4PD;hQi=>
HL60	NFrHWJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2nXdWlEPTB;MT64OkBvVQ>?	M3fnRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NU[2NlQ3Lz5zOEW2OlI1PjxxYU6=
A549	M1jPZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHNdW1KSzVyPUOuNlQhdk1?	MmexQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3Nk[yOFYoRjF6NU[2NlQ3RC:jPh?=
SW480	M132OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmS5TWM2OD1{Lk[5JI5O	MkfGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3Nk[yOFYoRjF6NU[2NlQ3RC:jPh?=
MCF7	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk[1TWM2OD1\|LkW1JI5O	MlqyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3Nk[yOFYoRjF6NU[2NlQ3RC:jPh?=
PC-3	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\BOmlEPTB;Mj61NUBvVQ>?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV4NkK0Okc,OTh3Nk[yOFY9N2F-
MMRU	NIjFdnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljMTWM2OD1{LkW3JI5O	M3zHUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NU[2NlQ3Lz5zOEW2OlI1PjxxYU6=
Hs68	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3zhVmlEPTB;PkGwJI5O	NEW1blA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW2OlI1Pid-MUi1OlYzPDZ:L3G+
hMSC-001F	NUD5VXQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4TGVmlEPTB;PkGwJI5O	NHnQUoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW2OlI1Pid-MUi1OlYzPDZ:L3G+
mammalian cells	NUfmTlY2TnWwY4Tpc44h[XO\|YYm=				MlLBTY5pcWKrdHnvckBw\iCKaYP0c45mKGSnYXPleJlt[XOnIESgbY4hdWGvbXHsbYFvKGOnbHzzMEBKSzVyIE2gNE42OSEQvF2u	Mn7ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTR3OES5N\|IoRjF2NUi0PVMzRC:jPh?=
mammalian cells	NVrGb2hUTnWwY4Tpc44h[XO\|YYm=				NVy0RXlOUW6qaXLpeIlwdiCxZjDIbZN1d26nIHTlZYNmfHmuYYPlJFEhcW6mdXPl[EBi[2W2eXzheIVlKGirc4TvcoUhcW5ibXHtcYFtcWGwIHPlcIx{NixiRVO1NEA:KDN4IN88UU4>	M1HW[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2NUi0PVMzLz5zNEW4OFk{OjxxYU6=
MCF7	NGfkcHlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NULDR\|V{T3Kxd4ToJIlvcGmkaYTpc44hd2ZiTVPGO{Bk\WyuczygTWM2OCB;IECuNFAxPzVizszNMi=>	NWq2SGVvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe5OVg{PDJpPkG3PVU5OzR{PD;hQi=>
A498	NV3Xd5p3S3m2b4TvfIlkcXS7IHHzd4F6		NFfLT203KGSjeYO=		MkDkR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVQ6QCClZXzsd{Bi\nSncjC2JIRigXNiYomgUXRVKGG\|c3H5MEBVT0liPTCwMlAzQCEQvF2u	NVToTVFRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OlcyPDZpPkKxPVY4OTR4PD;hQi=>
COLO205	NWLDc\|BtS3m2b4TvfIlkcXS7IHHzd4F6		NHzxUHQ3KGSjeYO=		MmfwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR29NVzJyNTDj[YxteyCjZoTldkA3KGSjeYOgZpkhVVSWIHHzd4F6NCCWR1mgQUAxNjB\|MTFOwG0v	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
U251	M2jCTWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NX;ofoo{PiCmYYnz		NX7BeI1WS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXTJ3MTDj[YxteyCjZoTldkA3KGSjeYOgZpkhVVSWIHHzd4F6NCCWR1mgQUAxNjB\|MTFOwG0v	Mlv1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NkexOFYoRjJzOU[3NVQ3RC:jPh?=
RXF393	NEW0UWdEgXSxdH;4bYNqfHliYYPzZZk>		NWHGbHgzPiCmYYnz		MmjqR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVnhHOzl\|IHPlcIx{KGGodHXyJFYh\GG7czDifUBOXFRiYYPzZZktKFSJSTC9JFAvODZ{IN88UU4>	M{e1NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[3NVQ3Lz5{MUm2O\|E1PjxxYU6=
MDA-MB-468	NYfFdG1YS3m2b4TvfIlkcXS7IHHzd4F6		M2Did\|Yh\GG7cx?=		NIPWRWREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtOFY5KGOnbHzzJIFnfGW{IE[g[IF6eyCkeTDNWHQh[XO\|YYmsJHRIUSB;IECuNFkh\|ryPLh?=	NEn6ZlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm2O\|E1Pid-MkG5OlcyPDZ:L3G+
COLO205	NWjsOpE6S3m2b4TvfIlkcXS7IHHzd4F6		Mlj5OkBl[Xm\|		NV76OlQ{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0:OT{KwOUBk\WyuczDh[pRmeiB4IHThfZMh[nliTWTUJIF{e2G7LDDMR\|UxKD1iMD6wPVIh\|ryPLh?=	NWLZT\|VRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OlcyPDZpPkKxPVY4OTR4PD;hQi=>
UACC257	Mm\ER5l1d3SxeHnjbZR6KGG\|c3H5		MlrsOkBl[Xm\|		MnHKR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWWFESzJ3NzDj[YxteyCjZoTldkA3KGSjeYOgZpkhVVSWIHHzd4F6NCCWR1mgQUAxNjB7NTFOwG0v	M1HyXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[3NVQ3Lz5{MUm2O\|E1PjxxYU6=
U251	MVrDfZRwfG:6aXPpeJkh[XO\|YYm=		MmPVOkBl[Xm\|		NXy0WINXS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXTJ3MTDj[YxteyCjZoTldkA3KGSjeYOgZpkhVVSWIHHzd4F6NCCOQ{WwJF0hOC5zMzFOwG0v	NVjkXXliRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OlcyPDZpPkKxPVY4OTR4PD;hQi=>
A498	MoLvR5l1d3SxeHnjbZR6KGG\|c3H5		MmjFOkBl[Xm\|		Mmn5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVQ6QCClZXzsd{Bi\nSncjC2JIRigXNiYomgUXRVKGG\|c3H5MEBNSzVyIE2gNE4zKM7:TT6=	NVvCdGd1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OlcyPDZpPkKxPVY4OTR4PD;hQi=>
NCI-H322M	M13Z[GN6fG:2b4jpZ4l1gSCjc4PhfS=>		M1jDbFYh\GG7cx?=		Mo\jR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUh\|MkLNJINmdGy\|IHHmeIVzKDZiZHH5d{BjgSCPVGSgZZN{[XluIGTHTUA:KDBwMkOg{txONg>?	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
SF295	Mo[4R5l1d3SxeHnjbZR6KGG\|c3H5		NWjJU3hYPiCmYYnz		MnLvR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2YzQTViY3XscJMh[W[2ZYKgOkBl[Xm\|IHL5JG1VXCCjc4PhfUwhXEeLIE2gNE4zPSEQvF2u	NGCyOYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm2O\|E1Pid-MkG5OlcyPDZ:L3G+
RXF393	NVTtUop3S3m2b4TvfIlkcXS7IHHzd4F6		M3XYOVYh\GG7cx?=		M1:0ZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHJZTjN7MzDj[YxteyCjZoTldkA3KGSjeYOgZpkhVVSWIHHzd4F6NCCOQ{WwJF0hOC5\|IN88UU4>	NV[ydGJORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OlcyPDZpPkKxPVY4OTR4PD;hQi=>
NCI60	M3rPOWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MUm2JIRigXN?		M1nITWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUTZyIHPlcIx{KGGodHXyJFYh\GG7czDifUBOXFRiYYPzZZktKFSJSTC9JFAvOzNizszNMi=>	NEfVN3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm2O\|E1Pid-MkG5OlcyPDZ:L3G+
SN12C	MmnPR5l1d3SxeHnjbZR6KGG\|c3H5		NEO3c5g3KGSjeYO=		MoO5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV24yOkNiY3XscJMh[W[2ZYKgOkBl[Xm\|IHL5JG1VXCCjc4PhfUwhXEeLIE2gNE4{PCEQvF2u	MlvxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NkexOFYoRjJzOU[3NVQ3RC:jPh?=
MDA-MB-231	MmmyR5l1d3SxeHnjbZR6KGG\|c3H5		MoL1OkBl[Xm\|		MoHxR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDh[pRmeiB4IHThfZMh[nliTWTUJIF{e2G7LDDUS2khRSByLkO1JO69VS5?	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
ACHN	NFPlU\|FEgXSxdH;4bYNqfHliYYPzZZk>		NXq1UFJ7PiCmYYnz		NGjDRpJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCS0iQIHPlcIx{KGGodHXyJFYh\GG7czDifUBOXFRiYYPzZZktKFSJSTC9JFAvPzNizszNMi=>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
SN12C	NX\hbXp6S3m2b4TvfIlkcXS7IHHzd4F6		MXi2JIRigXN?		NYT0dJc4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW05zMlOgZ4VtdHNiYX\0[ZIhPiCmYYnzJIJ6KE2WVDDhd5NigSxiTFO1NEA:KDFwNTFOwG0v	NIKzc409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm2O\|E1Pid-MkG5OlcyPDZ:L3G+
UO31	MmfBR5l1d3SxeHnjbZR6KGG\|c3H5		MoTLOkBl[Xm\|		MkPKR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWW8{OSClZXzsd{Bi\nSncjC2JIRigXNiYomgUXRVKGG\|c3H5MEBVT0liPTCxMlU2KM7:TT6=	M1fMclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[3NVQ3Lz5{MUm2O\|E1PjxxYU6=
Caki1	NFX5TY5EgXSxdH;4bYNqfHliYYPzZZk>		MXi2JIRigXN?		NG\iSVVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBE[WurMTDj[YxteyCjZoTldkA3KGSjeYOgZpkhVVSWIHHzd4F6NCCWR1mgQUAyNjh7IN88UU4>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
NCI60	M3fUV2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M3q4UVYh\GG7cx?=		M4D1UmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUTZyIHPlcIx{KGGodHXyJFYh\GG7czDifUBOXFRiYYPzZZktKEyFNUCgQUA{NjVizszNMi=>	MojtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NkexOFYoRjJzOU[3NVQ3RC:jPh?=
MDA-MB-231	NHLEXFNEgXSxdH;4bYNqfHliYYPzZZk>		M3jMWFYh\GG7cx?=		MmHNR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDh[pRmeiB4IHThfZMh[nliTWTUJIF{e2G7LDDMR\|UxKD1iND6wPEDPxE1w	NGrMbG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm2O\|E1Pid-MkG5OlcyPDZ:L3G+
MDA-MB-468	M3fobWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M1fTPFYh\GG7cx?=		NVXBTVZNS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{Bi\nSncjC2JIRigXNiYomgUXRVKGG\|c3H5MEBNSzVyIE2gOE4yPCEQvF2u	NGTmV5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm2O\|E1Pid-MkG5OlcyPDZ:L3G+
ACHN	MkfVR5l1d3SxeHnjbZR6KGG\|c3H5		MUi2JIRigXN?		MXzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBR2hPKGOnbHzzJIFnfGW{IE[g[IF6eyCkeTDNWHQh[XO\|YYmsJGxEPTBiPTC1MlM4KM7:TT6=	NYfjO2pURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OlcyPDZpPkKxPVY4OTR4PD;hQi=>
UACC257	MXHDfZRwfG:6aXPpeJkh[XO\|YYm=		NVHHU3FUPiCmYYnz		MmHTR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWWFESzJ3NzDj[YxteyCjZoTldkA3KGSjeYOgZpkhVVSWIHHzd4F6NCCOQ{WwJF0hPS52NjFOwG0v	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
NCI-H322M	MYjDfZRwfG:6aXPpeJkh[XO\|YYm=		M4XqVFYh\GG7cx?=		MXvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDN{Ml2gZ4VtdHNiYX\0[ZIhPiCmYYnzJIJ6KE2WVDDhd5NigSxiTFO1NEA:KDlwMEKg{txONg>?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
SF295	MlvlR5l1d3SxeHnjbZR6KGG\|c3H5		NGi4TYU3KGSjeYO=		NI\S[3VEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUTjJ7NTDj[YxteyCjZoTldkA3KGSjeYOgZpkhVVSWIHHzd4F6NCCOQ{WwJF0hOTBwMjFOwG0v	M4XCO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[3NVQ3Lz5{MUm2O\|E1PjxxYU6=
Caki1	NGjaTHJEgXSxdH;4bYNqfHliYYPzZZk>		Ml7NOkBl[Xm\|		NFe1d41EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBE[WurMTDj[YxteyCjZoTldkA3KGSjeYOgZpkhVVSWIHHzd4F6NCCOQ{WwJF0hOjBwOTFOwG0v	NX\MNmI{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OlcyPDZpPkKxPVY4OTR4PD;hQi=>
NCI-H23	NYPoTXdrSW62aYT1cY9zKGG\|c3H5	NYmyeIFLOS54IITvJFIvPCCvZz;r[y=>	Mnn0eZAhfG9iNTDkZZl{		MVnBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFI{KGOnbHzzJIlueGyjboTl[EBqdnS{YYDldol1d26nYXzsfUBqdiCvb4Xz[UBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJR2dW:{IHPlcIwh\3Kxd4ToJIF1KDFwNjD0c{AzNjRibXevb4ctKGmyIHHkcYlvcXO2ZYLl[EBwdiCmYYmgNUB1dyB2IH3lZZN2emWmIH;uJIRigSB3IHL5JIhwdGyxdzDmbYJmeiCjc4PhfS=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
NCI-H522	MVvBcpRqfHWvb4KgZZN{[Xl?	MVuxMlYhfG9iMj60JI1oN2up	MniweZAhfG9iNTDkZZl{		MXfBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFUzOiClZXzsd{BqdXCuYX70[YQhcW62cnHw[ZJqfG:wZXHscJkhcW5ibX;1d4Uh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB1fW2xcjDj[YxtKGe{b4f0bEBifCBzLk[geI8hOi52IH3nM4toNCCrcDDh[I1qdmm\|dHXy[YQhd25iZHH5JFEhfG9iNDDt[YF{fXKnZDDvckBl[XliNTDifUBpd2yub4eg[olj\XJiYYPzZZk>	MmKzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NkexOFYoRjJzOU[3NVQ3RC:jPh?=
OVCAR5	NYfQcoV3SW62aYT1cY9zKGG\|c3H5	NF\uVIQyNjZidH:gNk41KG2pL3vn	MXf1dEB1dyB3IHThfZM>		MkXQRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iT2\DRXI2KGOnbHzzJIlueGyjboTl[EBqdnS{YYDldol1d26nYXzsfUBqdiCvb4Xz[UBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJR2dW:{IHPlcIwh\3Kxd4ToJIF1KDFwNjD0c{AzNjRibXevb4ctKGmyIHHkcYlvcXO2ZYLl[EBwdiCmYYmgNUB1dyB2IH3lZZN2emWmIH;uJIRigSB3IHL5JIhwdGyxdzDmbYJmeiCjc4PhfS=>	M3rnOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[3NVQ3Lz5{MUm2O\|E1PjxxYU6=
SW620	MkPCRY51cXS3bX;yJIF{e2G7	NFPmRWoyNjZidH:gNk41KG2pL3vn	NW\PTHpXfXBidH:gOUBl[Xm\|		NH\qV5FCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTW\|YzOCClZXzsd{BqdXCuYX70[YQhcW62cnHw[ZJqfG:wZXHscJkhcW5ibX;1d4Uh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB1fW2xcjDj[YxtKGe{b4f0bEBifCBzLk[geI8hOi52IH3nM4toNCCrcDDh[I1qdmm\|dHXy[YQhd25iZHH5JFEhfG9iNDDt[YF{fXKnZDDvckBl[XliNTDifUBpd2yub4eg[olj\XJiYYPzZZk>	M4\y[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[3NVQ3Lz5{MUm2O\|E1PjxxYU6=
MDA-MB-435	M2fmRWFvfGm2dX3vdkBie3OjeR?=	NFzwSVcyNjZidH:gNk41KG2pL3vn	M2fXcJVxKHSxIEWg[IF6ew>?		NFnzOY5CdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNEO1JINmdGy\|IHntdIxidnSnZDDpcpRz[XCncnn0c45m[WyueTDpckBud3W\|ZTDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIIT1cY9zKGOnbHyg[5Jwf3SqIHH0JFEvPiC2bzCyMlQhdWdxa3esJIlxKGGmbXnubZN1\XKnZDDvckBl[XliMTD0c{A1KG2nYYP1doVlKG:wIHThfUA2KGK7IHjvcIxwfyCoaXLldkBie3OjeR?=	NV\XR5hLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OlcyPDZpPkKxPVY4OTR4PD;hQi=>
COLO205	NH7KS3hCdnSrdIXtc5Ih[XO\|YYm=	M3jkXVEvPiC2bzCyMlQhdWdxa3e=	M4HXXZVxKHSxIEWg[IF6ew>?		MXvBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCFT1zPNlA2KGOnbHzzJIlueGyjboTl[EBqdnS{YYDldol1d26nYXzsfUBqdiCvb4Xz[UBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJR2dW:{IHPlcIwh\3Kxd4ToJIF1KDFwNjD0c{AzNjRibXevb4ctKGmyIHHkcYlvcXO2ZYLl[EBwdiCmYYmgNUB1dyB2IH3lZZN2emWmIH;uJIRigSB3IHL5JIhwdGyxdzDmbYJmeiCjc4PhfS=>	NWnRWZhjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OlcyPDZpPkKxPVY4OTR4PD;hQi=>
LOXIMVI	NU\BOIxGSW62aYT1cY9zKGG\|c3H5	NWPCbYpLOS54IITvJFIvPCCvZz;r[y=>	M3fmRZVxKHSxIEWg[IF6ew>?		NVOwVolWSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUG9ZUU2YSTDj[YxteyCrbYDsZY51\WRiaX70doFx\XKrdH;u[YFtdHliaX6gcY92e2ViYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC2dX3vdkBk\WyuIHfyc5d1cCCjdDCxMlYhfG9iMj60JI1oN2upLDDpdEBi\G2rbnnzeIVz\WRib36g[IF6KDFidH:gOEBu\WG\|dYLl[EBwdiCmYYmgOUBjgSCqb3zsc5ch\mmkZYKgZZN{[Xl?	MmDGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NkexOFYoRjJzOU[3NVQ3RC:jPh?=
UACC62	NFHs[lVCdnSrdIXtc5Ih[XO\|YYm=	NE[wNlIyNjZidH:gNk41KG2pL3vn	M13JTpVxKHSxIEWg[IF6ew>?		MoPTRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVVHDR\|YzKGOnbHzzJIlueGyjboTl[EBqdnS{YYDldol1d26nYXzsfUBqdiCvb4Xz[UBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJR2dW:{IHPlcIwh\3Kxd4ToJIF1KDFwNjD0c{AzNjRibXevb4ctKGmyIHHkcYlvcXO2ZYLl[EBwdiCmYYmgNUB1dyB2IH3lZZN2emWmIH;uJIRigSB3IHL5JIhwdGyxdzDmbYJmeiCjc4PhfS=>	M3njflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[3NVQ3Lz5{MUm2O\|E1PjxxYU6=
MDA-MB-231	NFK0WWhCdnSrdIXtc5Ih[XO\|YYm=	NW\jV4pIOS54IITvJFIvPCCvZz;r[y=>	NIO2bIZ2eCC2bzC1JIRigXN?		NXL2OYxvSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDpcZBt[W62ZXSgbY51emGyZYLpeI9v\WGubImgbY4hdW:3c3WgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjD0eY1weiClZXzsJIdzd3e2aDDheEAyNjZidH:gNk41KG2pL3vnMEBqeCCjZH3pcol{fGW{ZXSgc44h\GG7IEGgeI8hPCCvZXHzeZJm\CCxbjDkZZkhPSCkeTDoc4xtd3diZnni[ZIh[XO\|YYm=	M4GxVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[3NVQ3Lz5{MUm2O\|E1PjxxYU6=
SF295	MULBcpRqfHWvb4KgZZN{[Xl?	NGPC[5UyNjZidH:gNk41KG2pL3vn	M1vmWJVxKHSxIEWg[IF6ew>?		MknORY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1[yPVUh[2WubIOgbY1xdGGwdHXkJIlvfHKjcHXybZRwdmWjbHz5JIlvKG2xdYPlJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geJVud3JiY3XscEBoem:5dHigZZQhOS54IITvJFIvPCCvZz;r[{whcXBiYXTtbY5qe3SncnXkJI9vKGSjeTCxJJRwKDRibXXhd5Vz\WRib36g[IF6KDViYomgbI9tdG:5IH\pZoVzKGG\|c3H5	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl4N{G0Okc,OjF7NkexOFY9N2F-
U251	NGf3e\|JCdnSrdIXtc5Ih[XO\|YYm=	NWfZUlJ2OS54IITvJFIvPCCvZz;r[y=>	MWr1dEB1dyB3IHThfZM>		M2\BVmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGWyOVEh[2WubIOgbY1xdGGwdHXkJIlvfHKjcHXybZRwdmWjbHz5JIlvKG2xdYPlJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geJVud3JiY3XscEBoem:5dHigZZQhOS54IITvJFIvPCCvZz;r[{whcXBiYXTtbY5qe3SncnXkJI9vKGSjeTCxJJRwKDRibXXhd5Vz\WRib36g[IF6KDViYomgbI9tdG:5IH\pZoVzKGG\|c3H5	NVPpOnlKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OlcyPDZpPkKxPVY4OTR4PD;hQi=>
OVRAC3	Mof1RY51cXS3bX;yJIF{e2G7	MlvzNU43KHSxIEKuOEBu\y:tZx?=	NYfKXGFjfXBidH:gOUBl[Xm\|		MXvBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCRVmLBR\|Mh[2WubIOgbY1xdGGwdHXkJIlvfHKjcHXybZRwdmWjbHz5JIlvKG2xdYPlJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geJVud3JiY3XscEBoem:5dHigZZQhOS54IITvJFIvPCCvZz;r[{whcXBiYXTtbY5qe3SncnXkJI9vKGSjeTCxJJRwKDRibXXhd5Vz\WRib36g[IF6KDViYomgbI9tdG:5IH\pZoVzKGG\|c3H5	MnLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NkexOFYoRjJzOU[3NVQ3RC:jPh?=
LLC	NH65TZRHfW6ldHnvckBie3OjeR?=				M{[2PWlvcGmkaYTpc44hd2ZiSFTBR{1u\WSrYYTl[EBJUUZvMXHsdIhiKGGldHn2bZR6KGmwIH3veZNmKEyOQzDj[YxteyxiSVO1NEA:KDJizszNMi=>	MkXsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|MEW2NVIoRjJ{M{C1OlEzRC:jPh?=
NCI-H522	NH7CRohIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				MYrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDV{MjDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHPvcI9zcW2ndILpZ{Bu\XSqb3SsJGdKPTBiPTCwMlAxOThizszNMi=>	M2X3OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{GzOlM5Lz5{M{OxN\|Y{QDxxYU6=
LOXIMVI	NUj2PJRWT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				M3LpZ2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGxQYEmPVlmgZ4VtdHNiYomgd5Vt\m:{aH;kZY1qdmViQjDjc4xwemmvZYTybYMhdWW2aH;kMEBIUTVyIE2gNE4xODJ3IN88UU4>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzM{[zPEc,OjN\|MUO2N\|g9N2F-
A549	NIfoNIlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NHzWS2FIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBCPTR7IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiY3;sc5JqdWW2cnnjJI1mfGixZDygS2k2OCB;IECuNFAzPiEQvF2u	M3nsWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{GzOlM5Lz5{M{OxN\|Y{QDxxYU6=
OVCAR5	NGfnOmlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NYPEcWw1T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWK1JINmdGy\|IHL5JJN2dG[xcnjv[IFucW6nIFKgZ49td3KrbXX0dolkKG2ndHjv[EwhT0l3MDC9JFAvODB{ODFOwG0v	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzM{[zPEc,OjN\|MUO2N\|g9N2F-
MKN74	M4PjNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NXn1WY1pT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUuQN{SgZ4VtdHNiYomgd5Vt\m:{aH;kZY1qdmViQjDjc4xwemmvZYTybYMhdWW2aH;kMEBIUTVyIE2gNE4xODNizszNMi=>	NYq4XnpXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVM3OzhpPkKzN\|E{PjN6PD;hQi=>
NCI-H460	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				MVHHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDR4MDDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHPvcI9zcW2ndILpZ{Bu\XSqb3SsJGdKPTBiPTCwMlAxOyEQvF2u	NGK0fHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxN\|Y{QCd-MkOzNVM3Ozh:L3G+
HCT116	NGHi[4JIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				MV7Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR3QyOTZiY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiClb3zvdolu\XS{aXOgcYV1cG:mLDDHTVUxKD1iMD6wNFMyKM7:TT6=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzM{[zPEc,OjN\|MUO2N\|g9N2F-
HCC2998	NGjld2VIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NUHFdFl{T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUEOFMkm5PEBk\WyuczDifUB{fWyob4Loc4RidWmwZTDCJINwdG:{aX3leJJq[yCvZYToc4QtKEeLNUCgQUAxNjByM{Gg{txONg>?	M3rlNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{GzOlM5Lz5{M{OxN\|Y{QDxxYU6=
MKN1	M322Smdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				M4P0NWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1MVjFiY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiClb3zvdolu\XS{aXOgcYV1cG:mLDDHTVUxKD1iMD6wNFMzKM7:TT6=	M{fwPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{GzOlM5Lz5{M{OxN\|Y{QDxxYU6=
SKOV3	M135R2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7				MkXlS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV2tQXjNiY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiClb3zvdolu\XS{aXOgcYV1cG:mLDDHTVUxKD1iMD6wNFM{KM7:TT6=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzM{[zPEc,OjN\|MUO2N\|g9N2F-
HT-29	MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				M4jrRWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhVNTJ7IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiY3;sc5JqdWW2cnnjJI1mfGixZDygS2k2OCB;IECuNFA{OyEQvF2u	NXH1SWVPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVM3OzhpPkKzN\|E{PjN6PD;hQi=>
KM12	M{TiXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				M3rwUmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGtOOTJiY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiClb3zvdolu\XS{aXOgcYV1cG:mLDDHTVUxKD1iMD6wNFM1KM7:TT6=	NW\Ib2lKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVM3OzhpPkKzN\|E{PjN6PD;hQi=>
DMS114	M1TGXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				M2HmSWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGROWzFzNDDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHPvcI9zcW2ndILpZ{Bu\XSqb3SsJGdKPTBiPTCwMlAxOzZizszNMi=>	M3z3UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{GzOlM5Lz5{M{OxN\|Y{QDxxYU6=
SF539	NIr5S5ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NGTVelBIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUTjV\|OTDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHPvcI9zcW2ndILpZ{Bu\XSqb3SsJGdKPTBiPTCwMlAxOzZizszNMi=>	M3X2V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{GzOlM5Lz5{M{OxN\|Y{QDxxYU6=
U251	NGjzZpVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NXq1VWI{T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hXTJ3MTDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHPvcI9zcW2ndILpZ{Bu\XSqb3SsJGdKPTBiPTCwMlAxOzlizszNMi=>	NWW2colPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVM3OzhpPkKzN\|E{PjN6PD;hQi=>
SF295	MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				MV;Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDTSlI6PSClZXzsd{BjgSC\|dXzmc5Jpd2SjbXnu[UBDKGOxbH;ybY1mfHKrYzDt[ZRpd2RuIFfJOVAhRSByLkCwOEDPxE1w	Mn[3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUO2N\|goRjJ\|M{GzOlM5RC:jPh?=
MCF7	MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				M1TsV2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1ETjdiY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiClb3zvdolu\XS{aXOgcYV1cG:mLDDHTVUxKD1iMD6wNFQzKM7:TT6=	MonpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUO2N\|goRjJ\|M{GzOlM5RC:jPh?=
NCI-H23	MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				M2XrT2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkOgZ4VtdHNiYomgd5Vt\m:{aH;kZY1qdmViQjDjc4xwemmvZYTybYMhdWW2aH;kMEBIUTVyIE2gNE4xODR4IN88UU4>	NXuzXnR{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVM3OzhpPkKzN\|E{PjN6PD;hQi=>
OVCAR3	Ml71S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MUXHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDPWmNCWjNiY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiClb3zvdolu\XS{aXOgcYV1cG:mLDDHTVUxKD1iMD6wNFQ3KM7:TT6=	M2C1T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{GzOlM5Lz5{M{OxN\|Y{QDxxYU6=
MKN7	Ml\4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NGrmcY9Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOU055IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiY3;sc5JqdWW2cnnjJI1mfGixZDygS2k2OCB;IECuNFA1QSEQvF2u	M2DHUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{GzOlM5Lz5{M{OxN\|Y{QDxxYU6=
SF268	MnLyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NEO2RY5Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUTjJ4ODDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHPvcI9zcW2ndILpZ{Bu\XSqb3SsJGdKPTBiPTCwMlAxPDlizszNMi=>	NFnzU5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxN\|Y{QCd-MkOzNVM3Ozh:L3G+
MDA-MB-231	Ml3WS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				Mn\wS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDifUB{fWyob4Loc4RidWmwZTDCJINwdG:{aX3leJJq[yCvZYToc4QtKEeLNUCgQUAxNjByNUWg{txONg>?	Mm\vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUO2N\|goRjJ\|M{GzOlM5RC:jPh?=
OVCAR8	MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				M3j3cGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GUODDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHPvcI9zcW2ndILpZ{Bu\XSqb3SsJGdKPTBiPTCwMlAxPTVizszNMi=>	NEXwSJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxN\|Y{QCd-MkOzNVM3Ozh:L3G+
DMS273	NGHjfXFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NH2zPWdIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBFVVN{N{OgZ4VtdHNiYomgd5Vt\m:{aH;kZY1qdmViQjDjc4xwemmvZYTybYMhdWW2aH;kMEBIUTVyIE2gNE4xODV6IN88UU4>	NYX6e3VNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVM3OzhpPkKzN\|E{PjN6PD;hQi=>
DU145	MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				NEPORotIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBFXTF2NTDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHPvcI9zcW2ndILpZ{Bu\XSqb3SsJGdKPTBiPTCwMlAxPiEQvF2u	NU[yV\|UzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVM3OzhpPkKzN\|E{PjN6PD;hQi=>
RXF631L	M{HtO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7				M{jRUWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHJZTjZ\|MVygZ4VtdHNiYomgd5Vt\m:{aH;kZY1qdmViQjDjc4xwemmvZYTybYMhdWW2aH;kMEBIUTVyIE2gNE4xODZ4IN88UU4>	NXOwUHQ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVM3OzhpPkKzN\|E{PjN6PD;hQi=>
HBC4	MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				M3u0OGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhDSzRiY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiClb3zvdolu\XS{aXOgcYV1cG:mLDDHTVUxKD1iMD6wNFY6KM7:TT6=	NInzcpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxN\|Y{QCd-MkOzNVM3Ozh:L3G+
SNB75	M{G3Tmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NH;PWGNIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUVkJ5NTDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHPvcI9zcW2ndILpZ{Bu\XSqb3SsJGdKPTBiPTCwMlAxPzJizszNMi=>	M3T4T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{GzOlM5Lz5{M{OxN\|Y{QDxxYU6=
BSY1	M{W4b2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NXHV[\|hFT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hSlO\MTDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHPvcI9zcW2ndILpZ{Bu\XSqb3SsJGdKPTBiPTCwMlAxQDVizszNMi=>	M4CwWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{GzOlM5Lz5{M{OxN\|Y{QDxxYU6=
NCI-H226	MkntS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MWnHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDJ{NjDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHPvcI9zcW2ndILpZ{Bu\XSqb3SsJGdKPTBiPTCwMlAxQDlizszNMi=>	NVXNZZFQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVM3OzhpPkKzN\|E{PjN6PD;hQi=>
SNB78	NV3SUHZoT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NFLZXWdIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUVkJ5ODDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHPvcI9zcW2ndILpZ{Bu\XSqb3SsJGdKPTBiPTCwMlAxQTZizszNMi=>	MmfHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUO2N\|goRjJ\|M{GzOlM5RC:jPh?=
HBC5	MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				M4TuPWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhDSzViY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiClb3zvdolu\XS{aXOgcYV1cG:mLDDHTVUxKD1iMD6wNVMh\|ryPLh?=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzM{[zPEc,OjN\|MUO2N\|g9N2F-
MKN45	NFrvZWhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				MWDHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNT241PSClZXzsd{BjgSC\|dXzmc5Jpd2SjbXnu[UBDKGOxbH;ybY1mfHKrYzDt[ZRpd2RuIFfJOVAhRSByLkCxOEDPxE1w	NVT2VopWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVM3OzhpPkKzN\|E{PjN6PD;hQi=>
MKN28	NVLzPFh1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				MoPYS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUWtPOjhiY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiClb3zvdolu\XS{aXOgcYV1cG:mLDDHTVUxKD1iMD6wNVch\|ryPLh?=	NV:xb\|RJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVM3OzhpPkKzN\|E{PjN6PD;hQi=>
PC3	M3;LVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				M4X2V2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHBEOyClZXzsd{BjgSC\|dXzmc5Jpd2SjbXnu[UBDKGOxbH;ybY1mfHKrYzDt[ZRpd2RuIFfJOVAhRSByLkCxPEDPxE1w	M1q1XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{GzOlM5Lz5{M{OxN\|Y{QDxxYU6=
ACHN	Mn[4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NE\iSG5Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBCS0iQIHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiY3;sc5JqdWW2cnnjJI1mfGixZDygS2k2OCB;IECuNFIh\|ryPLh?=	M171OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{GzOlM5Lz5{M{OxN\|Y{QDxxYU6=
OVCAR4	NF\oOY1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NX:2SHljT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWK0JINmdGy\|IHL5JJN2dG[xcnjv[IFucW6nIFKgZ49td3KrbXX0dolkKG2ndHjv[EwhT0l3MDC9JFAvODJizszNMi=>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzM{[zPEc,OjN\|MUO2N\|g9N2F-
St-4	NEXGXopIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NF3xdW1Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUfC12IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiY3;sc5JqdWW2cnnjJI1mfGixZDygS2k2OCB;IECuNFIzKM7:TT6=	NVrtO5MyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVM3OzhpPkKzN\|E{PjN6PD;hQi=>
HCT15	MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				MXjHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR3QyPSClZXzsd{BjgSC\|dXzmc5Jpd2SjbXnu[UBDKGOxbH;ybY1mfHKrYzDt[ZRpd2RuIFfJOVAhRSByLkS1JO69VS5?	M4HWSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{GzOlM5Lz5{M{OxN\|Y{QDxxYU6=
CD4+ T	MV\GeY5kfGmxbjDhd5NigQ>?		MkDrO{Bl[Xm\|		NW\sU5NwWmWjY4TpeoF1cW:wIH;mJIxifGWwdDDITXYyKE6OND2zMWx2[yCneIDy[ZN{cW:wIHnuJIh2dWGwIH7hbZZmKEOGNDugWEBk\WyuczD0doVifGWmIEeg[IF6eyCyb4P0MYlv\mWldHnvckBu\WG\|dYLl[EBi\nSncjC0PEBpenNiYomgcJVucW6nc3PlcoNmKHCuYYTlJJJm[WSncjDhcoFtgXOrczygSWM2OCB;IECuNFA{KM7:TT6=	NFfk[nQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES5OVExPSd-MkS0PVUyODV:L3G+
NCI-H522	NWL4RXhqS3m2b4TvfIlkcXS7IHHzd4F6				MofaR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUh3MkKgZ4VtdHNiYomgV3JDKGG\|c3H5MEBIUTVyIE2gNE4xODF6IN88UU4>	M3\R[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
LOXIMVI	MnHlR5l1d3SxeHnjbZR6KGG\|c3H5				M2f4TGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxQYEmPVlmgZ4VtdHNiYomgV3JDKGG\|c3H5MEBIUTVyIE2gNE4xODJ3IN88UU4>	NFTzS4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW4PVQ5Pid-MkS1PFk1QDZ:L3G+
A549	NWTxVWVXS3m2b4TvfIlkcXS7IHHzd4F6				MYjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NEA:KDBwMECyOkDPxE1w	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6OUS4Okc,OjR3OEm0PFY9N2F-
OVCAR5	MX\DfZRwfG:6aXPpeJkh[XO\|YYm=				M2X1UWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG9XS0GUNTDj[YxteyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCwMlAxOjhizszNMi=>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6OUS4Okc,OjR3OEm0PFY9N2F-
NCI-H460	MkHsR5l1d3SxeHnjbZR6KGG\|c3H5				MmTuR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUh2NkCgZ4VtdHNiYomgV3JDKGG\|c3H5MEBIUTVyIE2gNE4xODNizszNMi=>	M1XYd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
MKN74	M2radWN6fG:2b4jpZ4l1gSCjc4PhfS=>				M4PEW2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1MVjd2IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuNFA{KM7:TT6=	NEnOb4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW4PVQ5Pid-MkS1PFk1QDZ:L3G+
HCC2998	MmjSR5l1d3SxeHnjbZR6KGG\|c3H5				MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR2MzQTl6IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuNFA{OSEQvF2u	NW\xWHhKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PFk1QDZpPkK0OVg6PDh4PD;hQi=>
HCT116	NIC4TVdEgXSxdH;4bYNqfHliYYPzZZk>				MXTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMD6wNFMyKM7:TT6=	MlnhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OEm0PFYoRjJ2NUi5OFg3RC:jPh?=
MKN1	NELFV3ZEgXSxdH;4bYNqfHliYYPzZZk>				MXXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNT24yKGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NEA:KDBwMECzNkDPxE1w	M2qxflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
HT-29	Mof6R5l1d3SxeHnjbZR6KGG\|c3H5				MYjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVAhRSByLkCwN\|Mh\|ryPLh?=	NXXxfmVoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PFk1QDZpPkK0OVg6PDh4PD;hQi=>
SKOV3	NGLCfWpEgXSxdH;4bYNqfHliYYPzZZk>				MXzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT29XOyClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVAhRSByLkCwN\|Mh\|ryPLh?=	M1LyZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
KM12	MonCR5l1d3SxeHnjbZR6KGG\|c3H5				MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLUVEzKGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NEA:KDBwMECzOEDPxE1w	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6OUS4Okc,OjR3OEm0PFY9N2F-
SF539	MVjDfZRwfG:6aXPpeJkh[XO\|YYm=				NYHSO3Z7S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0Z3M{mgZ4VtdHNiYomgV3JDKGG\|c3H5MEBIUTVyIE2gNE4xODN4IN88UU4>	NXnONnFDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PFk1QDZpPkK0OVg6PDh4PD;hQi=>
293T	NIPGbZlHfW6ldHnvckBie3OjeR?=		MYizNEBucW6\|		MoOzTY5pcWKrdHnvckBw\iCqdX3hckBJTEGFMTDlfJBz\XO\|ZXSgbY4hcHWvYX6gNlk{XCClZXzsd{B2e2mwZzDBZ{1MT0yJSzjBZ{kuVUODIHHzJJN2[nO2cnH0[UBi\nSncjCzNEBucW6\|IHL5JIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvODB\|NjFOwG0v	M2PzOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
DMS114	NU\LfphMS3m2b4TvfIlkcXS7IHHzd4F6				NGXESnREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFVVNzMUSgZ4VtdHNiYomgV3JDKGG\|c3H5MEBIUTVyIE2gNE4xODN4IN88UU4>	NWO0ZXozRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PFk1QDZpPkK0OVg6PDh4PD;hQi=>
U251	MVHDfZRwfG:6aXPpeJkh[XO\|YYm=				NHP2fJJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWOjVzIHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuNFA{QSEQvF2u	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6OUS4Okc,OjR3OEm0PFY9N2F-
SF295	MXjDfZRwfG:6aXPpeJkh[XO\|YYm=				MmXJR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2YzQTViY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMD6wNFQh\|ryPLh?=	M3r5ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
MCF7	NXHYdGp3S3m2b4TvfIlkcXS7IHHzd4F6				MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NEA:KDBwMEC0NkDPxE1w	M2fPV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
OVCAR3	NX3qd2E4S3m2b4TvfIlkcXS7IHHzd4F6				MnjER5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gU3ZESVJ\|IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuNFA1PiEQvF2u	M3X0N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
NCI-H23	NWTBVFBlS3m2b4TvfIlkcXS7IHHzd4F6				NI\aeWZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lvSEKzJINmdGy\|IHL5JHNTSiCjc4PhfUwhT0l3MDC9JFAvODB2NjFOwG0v	NUDuOJo6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PFk1QDZpPkK0OVg6PDh4PD;hQi=>
SF268	NITJ[Y5EgXSxdH;4bYNqfHliYYPzZZk>				Mk\3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2YzPjhiY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMD6wNFQ6KM7:TT6=	NIna[ng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW4PVQ5Pid-MkS1PFk1QDZ:L3G+
MKN7	MV;DfZRwfG:6aXPpeJkh[XO\|YYm=				M3G4[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1MVjdiY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMD6wNFQ6KM7:TT6=	NH71dGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW4PVQ5Pid-MkS1PFk1QDZ:L3G+
OVCAR8	NW\Zb4hCS3m2b4TvfIlkcXS7IHHzd4F6				NWjNU2tTS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hV1[FQWK4JINmdGy\|IHL5JHNTSiCjc4PhfUwhT0l3MDC9JFAvODB3NTFOwG0v	NFrCNHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW4PVQ5Pid-MkS1PFk1QDZ:L3G+
MDA-MB-231	Mn7PR5l1d3SxeHnjbZR6KGG\|c3H5				NE[wOopEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NEA:KDBwMEC1OUDPxE1w	M1foSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
DMS273	NIrNUJZEgXSxdH;4bYNqfHliYYPzZZk>				MXXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEUXMzPzNiY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMD6wNFU5KM7:TT6=	NUfZOpRTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PFk1QDZpPkK0OVg6PDh4PD;hQi=>
DU145	MlHLR5l1d3SxeHnjbZR6KGG\|c3H5				NGjP[FZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCwMlAxPiEQvF2u	NHvjbmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW4PVQ5Pid-MkS1PFk1QDZ:L3G+
RXF631L	NH3tRoxEgXSxdH;4bYNqfHliYYPzZZk>				NGnMNoVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBTYEZ4M{HMJINmdGy\|IHL5JHNTSiCjc4PhfUwhT0l3MDC9JFAvODB4NjFOwG0v	M2XHUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
HBC4	M{TLPGN6fG:2b4jpZ4l1gSCjc4PhfS=>				NWLIfmNMS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEKFNDDj[YxteyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCwMlAxPjlizszNMi=>	MmLsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OEm0PFYoRjJ2NUi5OFg3RC:jPh?=
SNB75	NVvhPYdWS3m2b4TvfIlkcXS7IHHzd4F6				MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTUmI4PSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVAhRSByLkCwO\|Ih\|ryPLh?=	NWnmWm1wRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PFk1QDZpPkK0OVg6PDh4PD;hQi=>
BSY1	NW\Je\|J[S3m2b4TvfIlkcXS7IHHzd4F6				NV7qSGdDS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSlO\MTDj[YxteyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCwMlAxQDVizszNMi=>	M2Pzd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
NCI-H226	MmLSR5l1d3SxeHnjbZR6KGG\|c3H5				MXHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDJ{NjDj[YxteyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCwMlAxQDlizszNMi=>	NV3w[3o2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PFk1QDZpPkK0OVg6PDh4PD;hQi=>
SNB78	MXLDfZRwfG:6aXPpeJkh[XO\|YYm=				Mm\IR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV25DPzhiY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMD6wNFk3KM7:TT6=	NIfrbow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW4PVQ5Pid-MkS1PFk1QDZ:L3G+
HBC5	MUDDfZRwfG:6aXPpeJkh[XO\|YYm=				MX7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIRmM2KGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NEA:KDBwMEGzJO69VS5?	NGPGc\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW4PVQ5Pid-MkS1PFk1QDZ:L3G+
MKN45	M3LFU2N6fG:2b4jpZ4l1gSCjc4PhfS=>				M{H5UGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1MVjR3IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuNFE1KM7:TT6=	NXPseodJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PFk1QDZpPkK0OVg6PDh4PD;hQi=>
MKN28	M2HNSWN6fG:2b4jpZ4l1gSCjc4PhfS=>				NFLLOXFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOU05{ODDj[YxteyCkeTDTVmIh[XO\|YYmsJGdKPTBiPTCwMlAyPyEQvF2u	Mn;kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OEm0PFYoRjJ2NUi5OFg3RC:jPh?=
PC3	MoTBR5l1d3SxeHnjbZR6KGG\|c3H5				MkDZR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NEA:KDBwMEG4JO69VS5?	MoW0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OEm0PFYoRjJ2NUi5OFg3RC:jPh?=
ACHN	Mly4R5l1d3SxeHnjbZR6KGG\|c3H5				NILySGJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCS0iQIHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OCB;IECuNFIh\|ryPLh?=	MnrBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OEm0PFYoRjJ2NUi5OFg3RC:jPh?=
OVCAR4	NUfxb3hXS3m2b4TvfIlkcXS7IHHzd4F6				MU\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDPWmNCWjRiY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxKD1iMD6wNkDPxE1w	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV6OUS4Okc,OjR3OEm0PFY9N2F-
St-4	MlHlR5l1d3SxeHnjbZR6KGG\|c3H5				MUHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTeE01KGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NEA:KDBwMEKyJO69VS5?	MoHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OEm0PFYoRjJ2NUi5OFg3RC:jPh?=
293T	MlvRSpVv[3Srb36gZZN{[Xl?		NGS3OZM{OCCvaX7z		MWjJcohq[mm2aX;uJI9nKG2xdYPlJGhFSUN4IHX4dJJme3OnZDDpckBpfW2jbjCyPVNVKGOnbHzzJJV{cW6pIFHjMWtIVEeNKFHjLU1OS0FiYYOgd5Vje3S{YYTlJIFnfGW{IEOwJI1qdnNiYomg[ox2d3Knc3PlcoNmKGG\|c3H5MEBKSzVyIE2gNE4{QSEQvF2u	MlT5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3OEm0PFYoRjJ2NUi5OFg3RC:jPh?=
HCT15	NWT3XoJLS3m2b4TvfIlkcXS7IHHzd4F6				MXXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyPSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVAhRSByLkS1JO69VS5?	M3Wz[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUi5OFg3Lz5{NEW4PVQ5PjxxYU6=
mink Mv1Lu	NIf0SVZHfW6ldHnvckBie3OjeR?=		Ml;QNlQhcHK\|		NHjxdFhKdmO{ZXHz[UBqdiCqdX3hckB4cWymIIT5dIUheDJzIIDyc5RmcW5iZYjwdoV{e2mxbjDpckBucW6tIF32NWx2KGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDwNlEheHKxbX;0[ZIh[XO\|YYmgbY4heHKnc3XuZ4Uhd2ZiMD6xJI1OKGSrdHjpc5RpemWrdH;sMEBGSzFyMECgQUAxNjBzNUeg{txONg>?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl7N{W3PEc,OjR7OUe1O\|g9N2F-
HCT116	MXrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NFjZO5Q1QCCqcoO=		MonwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiNEigbJJ{KGmwIIDy[ZNmdmOnIH;mJGRVXCCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlAxOyEQvF2u	NGXrdGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG0O\|YyOid-MkWxOFc3OTJ:L3G+
MOLT4	MV\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NWK3bWNCPzJiaILz		NX[2RYdoSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNU2xVPCClZXzsd{Bi\nSncjC3NkBpenNiYomgR2NMQCCjc4PhfUwhT0l3MDC9JFAvODB{ME[g{txONg>?	NYTIO2I2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zN\|E{OzRpPkK2N\|MyOzN2PD;hQi=>
DU145	NVPSSIpvSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NFnheWc4OiCqcoO=		MmLORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCGVUG0OUBk\WyuczDh[pRmeiB5MjDodpMh[nliQ1PLPEBie3OjeTygS2k2OCB;IECuNFAzPTVizszNMi=>	NXf4OXh5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zN\|E{OzRpPkK2N\|MyOzN2PD;hQi=>
U937	NWDBSmFSSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Moj5O\|IhcHK\|		NWjxbnd{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPVM4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDDR2s5KGG\|c3H5MEBIUTVyIE2gNE4xODN2MTFOwG0v	NYH3dHFXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zN\|E{OzRpPkK2N\|MyOzN2PD;hQi=>
HLF	MoPVRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MYO3NkBpenN?		MXrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiORjDj[YxteyCjZoTldkA4OiCqcoOgZpkhS0ONODDhd5NigSxiR1m1NEA:KDBwMEC0PFkh\|ryPLh?=	NIX4W3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkOzNVM{PCd-Mk[zN\|E{OzR:L3G+
WI38	MUPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NF3qVok4OiCqcoO=		NHm4XmNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGfJN\|gh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPDT\|gh[XO\|YYmsJGdKPTBiPTCwMlAxPTN7IN88UU4>	NVXLPYRGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zN\|E{OzRpPkK2N\|MyOzN2PD;hQi=>
U937	NYTSbm8zTnWwY4Tpc44h[XO\|YYm=		NH7PNHkzPCCqcoO=		M2HscWlvcGmkaYTpc44hd2ZiSFTBR\|YhcW5iaIXtZY4hXTl\|NzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4Yh[WyyaHGteJVjcWyrbjDhZ4V1gWyjdHnvckBifCB3IH7NJJRwKDVidV2gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	NUfWSWtJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zN\|E{OzRpPkK2N\|MyOzN2PD;hQi=>
HCT116	NUTXRVJvSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NYqzNYM4PzJiaILz		MYXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDpcoN2[mG2ZXSg[o9zKDd{IHjyd{BjgSClb4XseIVzKGOxdX70[ZIhdWW2aH;kMEBKSzVyIE2gNE4xOjhizszNMi=>	Mo\FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2OEG2OVkoRjJ4NEixOlU6RC:jPh?=
IGROV1/Pt1	NULQW4h5SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M3W0W\|czKGi{cx?=		NVuwTXU2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDJS3JQXjFxUISxJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KGOxdXz0[ZIh[2:3boTldkBu\XSqb3SsJGlEPTBiPTCwMlA5KM7:TT6=	Mnq3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2OEG2OVkoRjJ4NEixOlU6RC:jPh?=
IGROV1	NXjqRotMSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NXThN4pIPzJiaILz		MkjFRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCLR2LPWlEh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDD2bYFjcWyrdImgbY5kfWKjdHXkJIZweiB5MjDodpMh[nliY3;1cJRmeiClb4XueIVzKG2ndHjv[EwhUUN3MDC9JFAvOjJizszNMi=>	NGPBfVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkS4NVY2QSd-Mk[0PFE3PTl:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p21 / Cyclin D1; PubMed: 19682393 J Mol Signal NIH 3T3 cells stably expressing the indicated proteins were treated with DMSO (Vehicle) or the indicated concentration of romidepsin for 24 h. Cell lysates were analyzed by western blotting with antibodies to cyclin D1, p21 and β-actin (loading control). Data shown are representative of at least two independent experiments. AcH3(K9) / Ac-α-Tubulin(K40) / Ac-NFκB2(K310) p65 / 3MeH3(K27); PubMed: 26473529 Blood Cancer J Effects of romidepsin (Rom) on the levels of acetylated proteins and related enzymes. Cells were exposed to romidepsin for 48 h and total cell extracts were analyzed by western blot. HDAC3 / HDAC4 / HDAC6 / HDAC2; PubMed: 26473529 Blood Cancer J Effects of romidepsin (Rom) on the levels of acetylated proteins and related enzymes. Cells were exposed to romidepsin for 48 h and total cell extracts were analyzed by western blot. γH2AX / PARP1 / Cleaved caspase3 / BAK / p21(waf1/cip1) / XIAP; PubMed: 26473529 Blood Cancer J Western blot analysis of proteins involved in DNA-damage response and apoptosis. Established cell lines were exposed to different concentrations of romidepsin (Rom) for 48 h and total cell extracts were analyzed. Cyclin E1 / BRCA1 / E2F1 / Cleaved PARP / H3Ac; PubMed: 27444036 Gynecol Oncol Western blot analysis of the effects of panobinostat (25 nM), vorinostat (5 µM) and romidepsin (10 nM) on expression of cyclin E1, E2F1, BRCA1, cleaved PARP and acetylated histone H3 in OVCAR-3 cells. Actin and histone H3 were loading controls. pAKT(S473) / pAKT(T308) / AKT; PubMed: 25492515 Cancer Sci Western blot analysis of phosphorylated AKT in PC3 cells. Cells were treated for 3 h with various concentrations of FK228.	19682393 26473529 27444036 25492515
Growth inhibition assay	Cell viability; PubMed: 27444036 Gynecol Oncol Concentration-dependent effects of panobinostat and vorinostat in SRB viability assays in OVCAR-3 cells (72 h). Values are mean+SE of 3 independent experiments.	27444036
Immunofluorescence	SS18/TLE1; PubMed: 27120803 Oncotarget A significant decrease in detectable PLA signal following HDAC inhibition in SYO-1 cells. Cleaved caspase-3; PubMed: 22531354 J Ovarian Res TDP-B activates cleaved caspase-3 by immunofluorescence. Representative immunofluorescence staining for cleaved caspase 3 (green) in SKOV-3 ovarian cancer cells treated with 10 nM FK228, TDP-A or TDP-B after 24 h of exposure. The nuclei are stained with DAPI (blue).	27120803 22531354

In vivo

Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. ^[4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). ^[5]

Protocol

Kinase Assay: ^[1]	- Collapse HDAC-inhibitory activity: For the enzyme assay, 10 μL of [³H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [³H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
Cell Research: ^[3]	- Collapse Cell lines: HL60, Jurkat, A549, and MCF-7 Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 72 hours Method: Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan. (Only for Reference)
Animal Research: ^[5]	- Collapse Animal Models: Male scid mice inoculated i.p. with U-937 cells Dosages: ~1 mg/kg once or twice a week Administration: Treated i.p. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	10 mg/mL (18.49 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5%Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight	540.7
Formula	C₂₄H₃₆N₄O₆S₂
CAS No.	128517-07-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	FR 901228, NSC 630176
Smiles	CC=C1C(=O)NC(C(=O)OC2CC(=O)NC(C(=O)NC(CSSCCC=C2)C(=O)N1)C(C)C)C(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03770000	Active not recruiting	Drug: Tenalisib\|Drug: Romidepsin	T Cell Lymphoma	Rhizen Pharmaceuticals SA	March 12 2019	Phase 1\|Phase 2
NCT02616965	Recruiting	Drug: Romidepsin\|Drug: Brentuximab vedotin	Cutaneous T-cell Lymphoma (CTCL)	Fox Chase Cancer Center\|Seagen Inc.\|Celgene Corporation	February 22 2017	Phase 1
NCT02616874	Completed	Drug: MVA.HIVconsv vaccine\|Drug: Romidepsin	HIV	IrsiCaixa\|Germans Trias i Pujol Hospital\|Fundación FLS de Lucha Contra el Sida las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia\|Hospital Clinic of Barcelona\|Hospital de Sant Pau\|HIVACAT\|University of Oxford\|BCN Checkpoint	February 2016	Phase 1
NCT03141203	Active not recruiting	Drug: Romidepsin\|Drug: Carfilzomib	Peripheral T Cell Lymphoma	University of Birmingham\|Bloodwise\|Celgene\|Amgen	July 13 2015	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Pan HDAC Inhibitor

Panobinostat (LBH589) : Pan-HDAC inhibitor, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

CAY10603 ^New

CAY10603 (BML-281) is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

Domatinostat (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589, NVP-LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
Vorinostat (SAHA)

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.
Entinostat (MS-275)

Entinostat (MS-275, SNDX-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Romidepsin (FK228, Depsipeptide)